Ennishi, D <br/><br/>
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Nov 2008 
 - 1921-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdn392  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor--biosynthesis<br/>CD5 Antigens--biosynthesis<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Phenotype<br/>Prednisone--administration & dosage<br/>Proto-Oncogene Proteins c-bcl-2--biosynthesis<br/>Rituximab<br/>Vincristine--administration & dosage